SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign
Private Issuer
Pursuant to
Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of
May 2009
Commission File
Number: 000-31062
Oncolytics Biotech Inc.
(Translation of registrant’s name
into English)
Suite 210,
1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive
offices)
Indicate by check mark
whether the registrant files or will file annual reports under cover Form 20-F
or Form 40-F.
Indicate by check mark
if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): o
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper
of a Form 6-K if submitted solely to provide an attached annual report to
security holders.
Indicate by check mark
if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): o
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper
of a Form 6-K if submitted to furnish a report or other document that the
registrant foreign private issuer must furnish and make public under the laws of
the jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant’s “home country”), or under the rules of the home
country exchange on which the registrant’s securities are traded, as long as the
report or other document is not a press release, is not required to be and has
not been distributed to the registrant’s security holders, and, if discussing a
material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
EXPLANATORY
NOTE
This report on Form
6-K and the exhibits attached hereto are specifically incorporated by reference
in the registrant’s Registration Statement on Form F-10 (File
No. 333-151513) which was originally filed with the SEC on June 6,
2008, as amended June 17, 2008.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
| |
|
|
|
|
| |
Oncolytics Biotech
Inc.
(Registrant)
|
|
| Date: May 18, 2009 |
By: |
/s/ Doug
Ball |
|
| |
|
Doug Ball |
|
| |
|
Chief Financial Officer |
|
EXHIBIT INDEX
| |
|
|
| Number |
|
Description |
| |
|
|
99.1 |
|
Underwriting Agreement by and between the
Registrant and Bolder Investment Partners, Ltd., dated May 6, 2009 |
|
99.2 |
|
Warrant Indenture, dated May 13, 2009 |